We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Shares of Apellis rise on clinical data for rare blood disease drug
Health Health Headlines News
Shares of Apellis Pharmaceuticals Inc. gained 5.1% in premarket trading on Friday after it shared details from a late-stage clinical trial evaluating its experimental drug pegcetacoplan against Alexion Pharmaceuticals Inc.'s Soliris as a treatment for paroxysmal nocturnal hemoglobinuria. The study found that pegcetacoplan was better than Soliris in improving hemoglobin levels in adults with the rare blood disease. Soliris brought in $3.9 billion in revenue in 2019. Apellis said it plans to submit a new drug application for pegcetacoplan to the Food and Drug Administration in the second half of the year. Its stock is down 0.5% year-to-date, while the S&P 500 has declined 7.1%.